Figure 1.
Figure 1. Changes in bone marrow disease burden versus serum IgM levels at 6 months following initiation of Everolimus in previously untreated WM patients.

Changes in bone marrow disease burden versus serum IgM levels at 6 months following initiation of Everolimus in previously untreated WM patients.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal